Skip to main content

Table 2 Change from baseline in levels of airway inflammatory markers

From: Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma

Marker

SFC (n = 33)

FP/M (n = 33)

Treatment difference (95% CI)

Ā 

Baseline

Change* (95% CI)

Baseline

Change* (95% CI)

Ā 

Primary markers (median)

Neutrophils (%)

37.40

-2.30 (-16.80, 14.70)

28.00

3.00 (-7.20, 15.50)

-9.40 (-26.50, 6.40)

Eosinophils (%)

1.20

-0.50 (-2.80, 0.80)

1.00

-0.50 (-1.00, 0.00)

0.20 (-1.50, 1.50)

Lymphocytes (%)

0.00

0.00 (-0.30, 0.50)

0.00

0.00 (0.00, 0.00)

0.00 (-0.30, 0.50)

Macrophages (%)

45.40

4.00 (-10.70, 15.20)

64.00

-0.50 (-8.70, 10.80)

1.70 (-12.60, 17.20)

Epithelial cells (%)

3.40

0.00 (-4.30, 8.00)

6.00

0.00 (-3.50, 2.50)

2.20 (-2.80, 9.00)

Secondary marker (median)

IL-8 (ng/ml)

3.80

0.00 (-0.29, 5.55)

2.99

0.00 (-5.32, 1.11)

3.85 (-0.32, 8.08)

  1. * median change from baseline
  2. CI, confidence interval; FP/M, fluticasone propionate plus montelukast; n, number; SFC, salmeterol plus fluticasone propionate